The Oxford Academic Health Science Network (Oxford AHSN) and Sandoz have developed an informative animation on biosimilars with input from individuals living with inflammatory arthritis.
The short film, made in partnership with the National Rheumatoid Arthritis Society, aims to inform people in an easy-to-understand, accessible format about biosimilars, why they have been approved for use in the UK and what that may mean for patients and health professionals.
NRAS believes biosimilars to be an important addition to available treatments for autoimmune conditions including rheumatoid arthritis. They are a lower cost alternative to originator drugs. This allows the NHS to make potential savings when switching patients from an originator treatment to a biosimilar.
Dr James Rose, Clinical Innovation Adoption Manager at Oxford AHSN, said: “This animation would be an ideal aid for health professionals when discussing switching to a biosimilar with patients. We encourage health professionals to signpost their patients to this excellent resource which will help reduce any concerns or anxieties they may have.”
Watch the film here.